Show simple item record

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status

dc.contributor.authorSwaminathan, Shanker
dc.contributor.authorRisacher, Shannon L.
dc.contributor.authorYoder, Karmen K.
dc.contributor.authorWest, John D.
dc.contributor.authorShen, Li
dc.contributor.authorKim, Sungeun
dc.contributor.authorInlow, Mark
dc.contributor.authorForoud, Tatiana
dc.contributor.authorJagust, William J.
dc.contributor.authorKoeppe, Robert A.
dc.contributor.authorMathis, Chester A.
dc.contributor.authorShaw, Leslie M.
dc.contributor.authorTrojanowski, John Q.
dc.contributor.authorSoares, Holly
dc.contributor.authorAisen, Paul S.
dc.contributor.authorPetersen, Ronald C.
dc.contributor.authorWeiner, Michael W.
dc.contributor.authorSaykin, Andrew J.
dc.date.accessioned2020-01-13T15:03:37Z
dc.date.available2020-01-13T15:03:37Z
dc.date.issued2014-01
dc.identifier.citationSwaminathan, Shanker; Risacher, Shannon L.; Yoder, Karmen K.; West, John D.; Shen, Li; Kim, Sungeun; Inlow, Mark; Foroud, Tatiana; Jagust, William J.; Koeppe, Robert A.; Mathis, Chester A.; Shaw, Leslie M.; Trojanowski, John Q.; Soares, Holly; Aisen, Paul S.; Petersen, Ronald C.; Weiner, Michael W.; Saykin, Andrew J. (2014). "Association of plasma and cortical amyloid beta is modulated by APOE ε4 status." Alzheimer’s & Dementia 10(1): e9-e18.
dc.identifier.issn1552-5260
dc.identifier.issn1552-5279
dc.identifier.urihttps://hdl.handle.net/2027.42/152522
dc.description.abstractBackgroundApolipoprotein E (APOE) ε4 allele’s role as a modulator of the relationship between soluble plasma amyloid beta (Aβ) and fibrillar brain Aβ measured by Pittsburgh compound B positron emission tomography ([11C]PiB PET) has not been assessed.MethodsNinety‐six Alzheimer’s Disease Neuroimaging Initiative participants with [11C]PiB scans and plasma Aβ1–40 and Aβ1–42 measurements at the time of PET scanning were included. Regional and voxelwise analyses of [11C]PiB data were used to determine the influence of APOE ε4 allele on association of plasma Aβ1–40, Aβ1–42, and Aβ1–40/Aβ1–42 with [11C]PiB uptake.ResultsIn APOE ε4− but not ε4+ participants, positive relationships between plasma Aβ1–40/Aβ1–42 and [11C]PiB uptake were observed. Modeling the interaction of APOE and plasma Aβ1–40/Aβ1–42 improved the explained variance in [11C]PiB binding compared with using APOE and plasma Aβ1–40/Aβ1–42 as separate terms.ConclusionsThe results suggest that plasma Aβ is a potential Alzheimer’s disease biomarker and highlight the importance of genetic variation in interpretation of plasma Aβ levels.
dc.publisherWiley Periodicals, Inc.
dc.publisherALZHEIMER’S & DEMENTIA
dc.subject.otherPittsburgh compound B
dc.subject.otherAlzheimer’s disease
dc.subject.otherMild cognitive impairment
dc.subject.otherAlzheimer’s Disease Neuroimaging Initiative
dc.subject.otherAmyloid beta
dc.subject.otherPlasma amyloid beta
dc.subject.otherPositron emission tomography
dc.subject.otherApolipoprotein E
dc.titleAssociation of plasma and cortical amyloid beta is modulated by APOE ε4 status
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152522/1/alzjjalz201301007.pdf
dc.identifier.doi10.1016/j.jalz.2013.01.007
dc.identifier.sourceAlzheimer’s & Dementia
dc.identifier.citedreferenceW.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, E.M. Reiman, et al. Relationships between biomarkers in aging and dementia. Neurology. 73: 2009; 1193 – 1199
dc.identifier.citedreferenceG.D. Rabinovici, W.J. Jagust. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 21: 2009; 117 – 128
dc.identifier.citedreferenceS.R. Choi, J.A. Schneider, D.A. Bennett, T.G. Beach, B.J. Bedell, S.P. Zehntner, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 26: 2012; 8 – 16
dc.identifier.citedreferenceC.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, et al. Use of florbetapir‐PET for imaging beta‐amyloid pathology. JAMA. 305: 2011; 275 – 283
dc.identifier.citedreferenceC.R. Jack Jr., V.J. Lowe, M.L. Senjem, S.D. Weigand, B.J. Kemp, M.M. Shiung, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 131: 2008; 665 – 680
dc.identifier.citedreferenceW.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D.P. Holt, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound‐B. Ann Neurol. 55: 2004; 306 – 319
dc.identifier.citedreferenceD.F. Wong, P.B. Rosenberg, Y. Zhou, A. Kumar, V. Raymont, H.T. Ravert, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F‐AV‐45 (florbetapir [corrected] F 18). J Nucl Med. 51: 2010; 913 – 920
dc.identifier.citedreferenceR. Mayeux, N. Schupf. Blood‐based biomarkers for Alzheimer’s disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging. 32: 2011; S10 – S19
dc.identifier.citedreferenceF. Song, A. Poljak, M. Valenzuela, R. Mayeux, G.A. Smythe, P.S. Sachdev. Meta‐analysis of plasma amyloid‐beta levels in Alzheimer’s disease. J Alzheimers Dis. 26: 2011; 365 – 375
dc.identifier.citedreferenceA. Koyama, O.I. Okereke, T. Yang, D. Blacker, D.J. Selkoe, F. Grodstein. Plasma amyloid‐beta as a predictor of dementia and cognitive decline: a systematic review and meta‐analysis. Arch Neurol. 69: 2012; 824 – 831
dc.identifier.citedreferenceM. Thambisetty, S. Lovestone. Blood‐based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark Med. 4: 2010; 65 – 79
dc.identifier.citedreferenceE.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 261: 1993; 921 – 923
dc.identifier.citedreferenceA.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George‐Hyslop, M.A. Pericak‐Vance, S.H. Joo, et al. Association of apolipoprotein E allele epsilon 4 with late‐onset familial and sporadic Alzheimer’s disease. Neurology. 43: 1993; 1467 – 1472
dc.identifier.citedreferenceL.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, R. Mayeux, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta‐analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 278: 1997; 1349 – 1356
dc.identifier.citedreferenceE.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, W. Lee, et al. Fibrillar amyloid‐beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A. 106: 2009; 6820 – 6825
dc.identifier.citedreferenceJ.B. Toledo, H. Vanderstichele, M. Figurski, P.S. Aisen, R.C. Petersen, M.W. Weiner, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 122: 2011; 401 – 413
dc.identifier.citedreferenceJ.E. Donahue, C.E. Johanson. Apolipoprotein E, amyloid‐beta, and blood–brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 67: 2008; 261 – 270
dc.identifier.citedreferenceJ.M. Castellano, J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, B.W. Patterson, et al. Human apoE isoforms differentially regulate brain amyloid‐beta peptide clearance. Sci Transl Med. 3: 2011, 89ra57
dc.identifier.citedreferenceM.J. Sharman, M. Morici, E. Hone, T. Berger, K. Taddei, I.J. Martins, et al. APOE genotype results in differential effects on the peripheral clearance of amyloid‐beta42 in APOE knock‐in and knock‐out mice. J Alzheimers Dis. 21: 2010; 403 – 409
dc.identifier.citedreferenceK. Nishitsuji, T. Hosono, T. Nakamura, G. Bu, M. Michikawa. Apolipoprotein E regulates the integrity of tight junctions in an isoform‐dependent manner in an in vitro blood–brain barrier model. J Biol Chem. 286: 2011; 17536 – 17542
dc.identifier.citedreferenceA.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, A.R. Shah, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 59: 2006; 512 – 519
dc.identifier.citedreferenceJ.K. Lui, S.M. Laws, Q.X. Li, V.L. Villemagne, D. Ames, B. Brown, et al. Plasma amyloid‐beta as a biomarker in Alzheimer’s disease: the AIBL study of aging. J Alzheimers Dis. 20: 2010; 1233 – 1242
dc.identifier.citedreferenceD.P. Devanand, N. Schupf, Y. Stern, R. Parsey, G.H. Pelton, P. Mehta, et al. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. Neurology. 77: 2011; 125 – 131
dc.identifier.citedreferenceM.W. Weiner, P.S. Aisen, C.R. Jack Jr., W.J. Jagust, J.Q. Trojanowski, L. Shaw, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 6: 2010; 202 – 211
dc.identifier.citedreferenceW.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, C.A. Mathis, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 6: 2010; 221 – 229
dc.identifier.citedreferenceK.J. Friston, A.P. Holmes, K.J. Worsley, J.P. Poline, C.D. Frith, R.S.J. Frackowiak. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 2: 1994; 189 – 210
dc.identifier.citedreferenceS. Swaminathan, L. Shen, S.L. Risacher, K.K. Yoder, J.D. West, S. Kim, et al. Amyloid pathway‐based candidate gene analysis of [(11)C]PiB‐PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav. 6: 2012; 1 – 15
dc.identifier.citedreferenceC.R. Jack Jr., M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, D. Harvey, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 27: 2008; 685 – 691
dc.identifier.citedreferenceS.L. Risacher, A.J. Saykin, J.D. West, L. Shen, H.A. Firpi, B.C. McDonald, et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res. 6: 2009; 347 – 361
dc.identifier.citedreferenceM.J. Figurski, T. Waligorska, J. Toledo, H. Vanderstichele, M. Korecka, V.M. Lee, et al. Improved protocol for measurement of plasma beta‐amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 8: 2012; 250 – 260
dc.identifier.citedreferenceA.J. Saykin, L. Shen, T.M. Foroud, S.G. Potkin, S. Swaminathan, S. Kim, et al. Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 6: 2010; 265 – 273
dc.identifier.citedreferenceR Core Team. R: a language and environment for statistical computing. 2012; R Foundation for Statistical Computing: Vienna, Austria
dc.identifier.citedreferenceJ.L. Lancaster, L.H. Rainey, J.L. Summerlin, C.S. Freitas, P.T. Fox, A.C. Evans, et al. Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward‐transform method. Hum Brain Mapp. 5: 1997; 238 – 242
dc.identifier.citedreferenceJ.L. Lancaster, M.G. Woldorff, L.M. Parsons, M. Liotti, C.S. Freitas, L. Rainey, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 10: 2000; 120 – 131
dc.identifier.citedreferenceW.J. Strittmatter, A.M. Saunders, D. Schmechel, M. Pericak‐Vance, J. Enghild, G.S. Salvesen, et al. Apolipoprotein E: high‐avidity binding to beta‐amyloid and increased frequency of type 4 allele in late‐onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 90: 1993; 1977 – 1981
dc.identifier.citedreferenceW.J. Strittmatter, K.H. Weisgraber, D.Y. Huang, L.M. Dong, G.S. Salvesen, M. Pericak‐Vance, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform‐specific effects and implications for late‐onset Alzheimer disease. Proc Natl Acad Sci U S A. 90: 1993; 8098 – 8102
dc.identifier.citedreferenceD.E. Schmechel, A.M. Saunders, W.J. Strittmatter, B.J. Crain, C.M. Hulette, S.H. Joo, et al. Increased amyloid beta‐peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late‐onset Alzheimer disease. Proc Natl Acad Sci U S A. 90: 1993; 9649 – 9653
dc.identifier.citedreferenceC. Bachmeier, D. Paris, D. Beaulieu‐Abdelahad, B. Mouzon, M. Mullan, F. Crawford. A multifaceted role for apoE in the clearance of beta‐amyloid across the blood–brain barrier. Neurodegener Dis. 11: 2013; 13 – 21
dc.identifier.citedreferenceC. Bachmeier, D. Beaulieu‐Abdelahad, F. Crawford, M. Mullan, D. Paris. Stimulation of the retinoid X receptor facilitates beta‐amyloid clearance across the blood–brain barrier. J Mol Neurosci. 49: 2013; 270 – 276
dc.identifier.citedreferenceP.B. Jones, K.W. Adams, A. Rozkalne, T.L. Spires‐Jones, T.T. Hshieh, T. Hashimoto, et al. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid‐beta in human Alzheimer brain. PLoS One. 6: 2011; e14586
dc.identifier.citedreferenceN. Bien‐Ly, Y. Andrews‐Zwilling, Q. Xu, A. Bernardo, C. Wang, Y. Huang. C‐terminal‐truncated apolipoprotein (apo) E4 inefficiently clears amyloid‐beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice. Proc Natl Acad Sci U S A. 108: 2011; 4236 – 4241
dc.identifier.citedreferenceAlzheimer’s Association. 2012 Alzheimer’s disease facts and figures. Alzheimers Dement. 8: 2012; 131 – 168
dc.identifier.citedreferenceH. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, J. Hardy, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 9: 2010; 560 – 574
dc.identifier.citedreferenceR.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, E. Kokmen. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 56: 1999; 303 – 308
dc.identifier.citedreferenceM.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 2011; 270 – 279
dc.identifier.citedreferenceL.M. Shaw, H. Vanderstichele, M. Knapik‐Czajka, C.M. Clark, P.S. Aisen, R.C. Petersen, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s Disease Neuroimaging Initiative subjects. Ann Neurol. 65: 2009; 403 – 413
dc.identifier.citedreferenceO.C. Okonkwo, M.M. Mielke, H.R. Griffith, A.R. Moghekar, R.J. O’Brien, L.M. Shaw, et al. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol. 68: 2011; 113 – 119
dc.identifier.citedreferenceP. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, O. Hansson. Cerebrospinal fluid levels of beta‐amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 69: 2012; 98 – 106
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.